Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel

BACKGROUND: In the AFFIRM trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration‐resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased prostate‐specific antigen (PSA) levels. The goal of this post hoc analysis wa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer
Main Authors: Armstrong, Andrew J., Saad, Fred, Phung, De, Dmuchowski, Carl, Shore, Neal D., Fizazi, Karim, Hirmand, Mohammad, Forer, David, Scher, Howard I., Bono, Johann De
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5484320/
https://ncbi.nlm.nih.gov/pubmed/28171710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30587
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares